Healthcare Biz Recap: GSK Shakes on Human Genome, Express Scripts Desires a Date Walgreen

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

GlaxoSmithKline (NYSE:GSK) shares move lower Wednesday as the firm modifies the terms of its $2.6 billion tender offer for Human Genome (NASDAQ:HGSI), which require that its quarry redeem or invalidate its poison pill.

Don’t Miss: Silicon Valley: DISRUPT Wall Street Now!!

Remarks of Express Scripts (NASDAQ:ESRX) CEO George Paz to the Wall Street Journal, include the fact he would “love to do a deal with Walgreen (NYSE:WAG)” that would bring back their expired contract, “if they’re willing to offer rates in line with everybody else.”. Paz also commented on the Medco merger, saying that while his company is frugal, Medco “had a different culture with respect to spending money”.

Shares of Incyte (NASDAQ:INCY) move down subsequent to a Morgan Stanley comment, that current consensus estimates don’t reflect myelofibrosis competition, which could affect the firm’s Jakafi sales.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

Investing Insights: Are YOU Still Overpaying for Facebook Shares?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business